Risk of gastrointestinal bleeding in Asian patients receiving oral anticoagulants for stroke prevention in atrial fibrillation.

Q2 Pharmacology, Toxicology and Pharmaceutics Drugs in Context Pub Date : 2024-08-13 eCollection Date: 2024-01-01 DOI:10.7573/dic.2024-5-5
Alejandro Bimbo Diaz, Jeremy Chow, Fan Kee Hoo, Gary Lee Chin Keong, Narayanaswamy Venketasubramanian, Nannette Rey, Gregorio Rogelio, Radhika Mehta
{"title":"Risk of gastrointestinal bleeding in Asian patients receiving oral anticoagulants for stroke prevention in atrial fibrillation.","authors":"Alejandro Bimbo Diaz, Jeremy Chow, Fan Kee Hoo, Gary Lee Chin Keong, Narayanaswamy Venketasubramanian, Nannette Rey, Gregorio Rogelio, Radhika Mehta","doi":"10.7573/dic.2024-5-5","DOIUrl":null,"url":null,"abstract":"<p><p>Non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly used for stroke prevention in atrial fibrillation. At the Asia Pacific Advancing Patient care with EdoXaban 2023 meeting, experts shared insights on gastrointestinal bleeding with NOACs for stroke prevention in atrial fibrillation in Asian clinical practice, where NOACs have gained widespread acceptance due to their favourable profiles. Gastrointestinal bleeding risk varies amongst NOACs, emphasizing the importance of diligent patient assessment, dosage selection and vigilant monitoring. Edoxaban emerged as a viable option with a low gastrointestinal bleeding risk profile in Asian compared with non-Asian patients, supporting its continued clinical utilization for appropriate patients.</p>","PeriodicalId":11362,"journal":{"name":"Drugs in Context","volume":"13 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11335362/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drugs in Context","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7573/dic.2024-5-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

Non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly used for stroke prevention in atrial fibrillation. At the Asia Pacific Advancing Patient care with EdoXaban 2023 meeting, experts shared insights on gastrointestinal bleeding with NOACs for stroke prevention in atrial fibrillation in Asian clinical practice, where NOACs have gained widespread acceptance due to their favourable profiles. Gastrointestinal bleeding risk varies amongst NOACs, emphasizing the importance of diligent patient assessment, dosage selection and vigilant monitoring. Edoxaban emerged as a viable option with a low gastrointestinal bleeding risk profile in Asian compared with non-Asian patients, supporting its continued clinical utilization for appropriate patients.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
接受口服抗凝剂预防心房颤动中风的亚洲患者胃肠道出血的风险。
非维生素 K 拮抗剂口服抗凝药(NOAC)越来越多地用于预防心房颤动患者中风。在亚太地区 "使用依多沙班 2023 推进患者护理 "会议上,专家们分享了亚洲临床实践中使用 NOACs 预防心房颤动卒中时消化道出血的见解,NOACs 因其良好的特性已被广泛接受。不同的 NOACs 有不同的胃肠道出血风险,这强调了认真评估患者、选择剂量和警惕监测的重要性。与非亚洲患者相比,埃多沙班在亚洲患者中的胃肠道出血风险较低,是一种可行的选择,支持在临床上继续用于合适的患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Drugs in Context
Drugs in Context Medicine-Medicine (all)
CiteScore
5.90
自引率
0.00%
发文量
63
审稿时长
9 weeks
期刊介绍: Covers all phases of original research: laboratory, animal and human/clinical studies, health economics and outcomes research, and postmarketing studies. Original research that shows positive or negative results are welcomed. Invited review articles may cover single-drug reviews, drug class reviews, latest advances in drug therapy, therapeutic-area reviews, place-in-therapy reviews, new pathways and classes of drugs. In addition, systematic reviews and meta-analyses are welcomed and may be published as original research if performed per accepted guidelines. Editorials of key topics and issues in drugs and therapeutics are welcomed. The Editor-in-Chief will also consider manuscripts of interest in areas such as technologies that support diagnosis, assessment and treatment. EQUATOR Network reporting guidelines should be followed for each article type. GPP3 Guidelines should be followed for any industry-sponsored manuscripts. Other Editorial sections may include Editorial, Case Report, Conference Report, Letter-to-the-Editor, Educational Section.
期刊最新文献
Good scientific practice of using worldwide post-marketing surveillance data to ensure safety with HAALI BDDE cross-linked hyaluronic acid fillers. Inclisiran for the treatment of hypercholesterolaemia. Liquid antipsychotics in the management of psychomotor agitation: a focus on promazine. Patient journey in cystinosis: focus on non-adherence and disease management. Pharmacovigilance monitoring and treatment adherence in patients on antihypertensive drugs at a tertiary care centre.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1